Nuclear Eg5 (kinesin Spindle Protein) Expression Predicts Docetaxel Response and Prostate Cancer Aggressiveness

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Oct 4

PMID 25277178

Citations 10

Authors

Michel D Wissing

Ellen S de Morree

Vincent O Dezentje

Jeroen T Buijs

Ronald R de Krijger

Vincent T H B M Smit

Wytske M van Weerden

Hans Gelderblom

Gabri van der Pluijm

Affiliations

Soon will be listed here.

Abstract

Novel biomarkers predicting prostate cancer (PCa) aggressiveness and docetaxel therapy response of PCa patients are needed. In this study the correlation between nuclear Eg5-expression, PCa docetaxel response and PCa aggressiveness was assessed. Immunohistochemical staining for nuclear Eg5 was performed on 117 archival specimens from 110 PCa patients treated with docetaxel between 2004 and 2012. Samples were histologically categorized as positive/negative. Median follow-up time from diagnosis was 11.6 years. Nuclear Eg5-expression was significantly related to docetaxel response (p=0.036) in tissues acquired within three years before docetaxel initiation. Nuclear Eg5-expression was not related to Gleason-score (p=0.994). Survival of patients after docetaxel initiation did not differ based on nuclear Eg5-expression (p=0.540). Analyzing samples taken before hormonal therapy, overall survival and time to docetaxel use were significantly decreased in patients with nuclear Eg5-expressing tumors (p<0.01). Eg5-positive nuclei were found more frequently in T4-staged tumors (p=0.04), Gleason 8-10 tumors (p=0.08), and in metastasized tumors (p<0.01). Multivariate analyses indicated that nuclear Eg5-expression may be an independent parameter for tumor aggressiveness. Limitations of a retrospective analysis apply. In conclusion, nuclear Eg5-expression may be a predictive biomarker for docetaxel response in metastatic castrate-resistant PCa patients and a prognostic biomarker for hormone-naive PCa patients. Prospective validation studies are needed.

Citing Articles

Mitotic Functions and Characters of KIF11 in Cancers.

Gao W, Lu J, Yang Z, Li E, Cao Y, Xie L Biomolecules. 2024; 14(4).

PMID: 38672404 PMC: 11047945. DOI: 10.3390/biom14040386.

HELLS Knockdown Inhibits the Malignant Progression of Lung Adenocarcinoma Via Blocking Akt/CREB Pathway by Downregulating KIF11.

Yang G, Fu J, Wang J, Ding M Mol Biotechnol. 2024; 67(2):548-561.

PMID: 38478260 DOI: 10.1007/s12033-024-01066-0.

KIF26B Is Overexpressed in Medulloblastoma and Promotes Malignant Progression by Activating the PI3K/AKT Pathway.

Liu Y, Zhang X, Pan R, Liang X, Liu Q, Yang C Anal Cell Pathol (Amst). 2022; 2022:2552397.

PMID: 35866054 PMC: 9296275. DOI: 10.1155/2022/2552397.

KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.

Hu Z, Jiang Y, Sun H, Wang J, Zhai L, Yin Z Biomed Res Int. 2021; 2021:2676745.

PMID: 33490265 PMC: 7801104. DOI: 10.1155/2021/2676745.

Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme.

Chen B, Wang K, Yu S, Zhang C, Li G, Wang Z Oncol Lett. 2020; 20(5):187.

PMID: 32952656 PMC: 7479526. DOI: 10.3892/ol.2020.12049.

References

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

Wissing M, van Oort I, Gerritsen W, van den Eertwegh A, Coenen J, Bergman A . Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands. Clin Genitourin Cancer. 2013; 11(3):238-250.e1. DOI: 10.1016/j.clgc.2013.04.004. View

Lad L, Luo L, Carson J, Wood K, Hartman J, Copeland R . Mechanism of inhibition of human KSP by ispinesib. Biochemistry. 2008; 47(11):3576-85. DOI: 10.1021/bi702061g. View

Berges R, Vukanovic J, Epstein J, CarMichel M, Cisek L, Johnson D . Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res. 1995; 1(5):473-80. PMC: 4086477. View

Wissing M, van Diest P, van der Wall E, Gelderblom H . Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. Expert Opin Investig Drugs. 2013; 22(5):635-61. DOI: 10.1517/13543784.2013.789858. View

de Bono J, Oudard S, Ozguroglu M, Hansen S, Machiels J, Kocak I . Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376(9747):1147-54. DOI: 10.1016/S0140-6736(10)61389-X. View

Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K . Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy. Lung Cancer. 2006; 54(2):217-25. DOI: 10.1016/j.lungcan.2006.06.018. View

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

Scher H, Halabi S, Tannock I, Morris M, Sternberg C, Carducci M . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7):1148-59. PMC: 4010133. DOI: 10.1200/JCO.2007.12.4487. View

10.

Blagden S, Molife L, Seebaran A, Payne M, Reid A, Protheroe A . A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer. 2008; 98(5):894-9. PMC: 2266864. DOI: 10.1038/sj.bjc.6604264. View

11.

Kapitein L, Peterman E, Kwok B, Kim J, Kapoor T, Schmidt C . The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature. 2005; 435(7038):114-8. DOI: 10.1038/nature03503. View

12.

Jordan M, Wilson L . Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4(4):253-65. DOI: 10.1038/nrc1317. View

13.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

14.

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

15.

van Diest P . No consent should be needed for using leftover body material for scientific purposes. For. BMJ. 2002; 325(7365):648-51. View

16.

van Soest R, van Royen M, de Morree E, Moll J, Teubel W, Wiemer E . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013; 49(18):3821-30. DOI: 10.1016/j.ejca.2013.09.026. View

17.

Sun D, Lu J, Ding K, Bi D, Niu Z, Cao Q . The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma. Med Oncol. 2013; 30(1):476. DOI: 10.1007/s12032-013-0476-0. View

18.

Beer T, Goldman B, Synold T, Ryan C, Vasist L, Van Veldhuizen Jr P . Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer. 2008; 6(2):103-9. DOI: 10.3816/CGC.2008.n.016. View

19.

van Soest R, de Morree E, Shen L, Tannock I, Eisenberger M, de Wit R . Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study. Eur Urol. 2013; 66(2):330-6. DOI: 10.1016/j.eururo.2013.08.007. View

20.

Gupta A, Lotan Y, Ashfaq R, Roehrborn C, Raj G, Aragaki C . Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol. 2008; 55(5):1124-33. DOI: 10.1016/j.eururo.2008.06.054. View